BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
BillionToOne, Inc. insider Thomas P. Lynch, the General Counsel, Chief Compliance Officer and Secretary, reported option exercises and related share sales on September 8, 2026. He exercised options covering 20,000 shares of Class A Common Stock at exercise prices of $8.65, $11.55, $17.12 and $30.78 per share, all from previously disclosed, fully vested grants.
On the same date, he sold a total of 20,000 shares of Class A Common Stock in a series of open-market transactions at prices generally around $96–$101 per share, with several reported as weighted-average prices over stated intraday ranges. All transactions were made under a Rule 10b5-1 trading plan adopted on June 8, 2026.
BillionToOne, Inc. (BLLN) reports equity movements by Chairman and CEO Atay Oguzhan involving 20,000 shares. On September 8, 2026, 20,000 shares of Class B common stock were converted into 20,000 shares of Class A common stock at a 1:1 ratio, leaving 2,197,542 Class B shares held directly. On September 9, 2026, Oguzhan made a bona fide gift transfer of 20,000 Class A shares. Class B shares are convertible into Class A shares at the holder’s option and will automatically convert one-for-one upon specified future events.
BillionToOne, Inc. (BLLN) has a notice of proposed sale of restricted or control securities under Rule 144 for the account of David Tsao. The filing covers up to 1,750 Class A shares of BillionToOne, held at Fidelity Brokerage Services LLC, with an aggregate market value of $170,695.00, and an intended sale date of September 9, 2026 on NASDAQ. The notice also lists prior Rule 144 sales over the past three months by David Tsao and the Dt 2021 Irrevocable Trust, including 20,000 Class A shares sold for $2,045,326.00 and 3,500 shares for $355,145.00 on June 15, 2026. A remark states that today’s sale and those prior sales occurred in the Dt 2021 Irrevocable Trust account managed by Icontrust LLC as trustee, with Tsao as an account stakeholder.
BillionToOne, Inc. (BLLN) has a notice of proposed sale under Rule 144 for 20,000 shares of Class A common stock for the account of David Tsao, to be sold through Fidelity Brokerage Services LLC, in connection with a stock option exercise dated September 9, 2026.
The notice also lists multiple prior Class A share sales over the preceding three months by David Tsao and the Dt 2021 Irrevocable Trust, with David Tsao identified as an account stakeholder in the trust.
BillionToOne, Inc. (BLLN) received a notice that stockholder John R. Ten Bosch intends to sell 1,416 shares of Class A common stock of BillionToOne, Inc. under Rule 144. The shares were acquired on January 13, 2022 as pre-IPO shares from the issuer for cash.
The planned sale will be executed through Fidelity Brokerage Services LLC, and the filing lists an aggregate market value reference of $138,116.64 for the 1,416 shares as of September 9, 2026, with the Class A common stock listed on NASDAQ. The notice also reports several prior Class A sales by Ten Bosch during the preceding three months.
BillionToOne, Inc. (BLLN) director and Chief Technology Officer David Tsao reported a series of internal equity moves. On September 3, 2026, he converted 20,000 shares of Class B common stock into 20,000 shares of Class A common stock at a 1:1 ratio, leaving 2,305,108 Class B shares held directly. On September 8, 2026, he made a bona fide gift of 20,000 Class A shares at a reported price of $0.00 per share. Class B shares are convertible into Class A on a one-for-one basis at the holder’s option and will automatically convert on specified future events. No Rule 10b5-1 trading plan is reported for these transactions.
BillionToOne, Inc. (BLLN) received a notice under Rule 144 for a proposed sale of Class A shares by officer Thomas P. Lynch. The notice covers a planned sale of 20,000 Class A shares, with an indicated aggregate market value of $1,984,800 and reference outstanding shares of 42,644,388 as of the stated date.
The shares are expected to be sold through Fidelity Brokerage Services LLC on NASDAQ on or after September 8, 2026, in connection with a stock option exercise for cash with the issuer as the counterparty.
BillionToOne, Inc. (BLLN) director Krishna Kittu Kolluri reported a series of code J “other acquisition or disposition” transactions on August 26, 2026 involving a total of 562,686 shares of Class A Common Stock held indirectly through investment funds, SPVs and trusts. The transactions reflect pro-rata, in-kind distributions among Neotribe-managed entities and various Kolluri-related trusts, all for no additional consideration, rather than open-market trading. Across these restructuring movements, aggregate net shares were neutral, and Kolluri disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
BillionToOne, Inc. (BLLN) director and Chief Technology Officer David Tsao reported an option exercise and related share sale. On 2026-08-25, he exercised 10,000 stock options for Class A Common Stock at $2.80 per share, receiving 10,000 shares, and on the same date sold 10,000 shares at $100.00 per share. Following the exercise, he held 580,000 stock options for Class A Common Stock. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026, and the options exercised were fully vested and exercisable.
BillionToOne, Inc. (BLLN) insider ten Bosch John Roderick, SVP of Laboratory Operations, reported selling 1,417 shares of Class A Common Stock on August 25, 2026 at $100.00 per share in an open market or private transaction. Following this sale, he directly holds 26,467 shares. The sale was effected under a Rule 10b5-1 trading plan adopted on March 6, 2026.